skip to the content

Clinical Trials

Lapatinab in Endocrine-Resistant Metastic Breast Cancer

Protocol ID

06.06.105

Protocol Description

The purpose of this study is to determine what effects (both good and bad) adding an investigational drug called lapatinib to hormonal therapy has on metastatic breast cancer.

Eligibility Criteria

Patients with breast cancer that has spread to other areas in the body

Primary Investigator(s)

  • Lora Weiselberg, MD

Contact Information

Marjorie Fricano, RN
(516) 734-8942
mfricano@nshs.edu

Last Update

March 26, 2010
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Cancer:
top
top